EPRX

EFFECT - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

F-10/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatmentIn the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepointsThe number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to 25% at 24 and 52 weeks post treatment At baseline 31% of patients in Cohorts 7-9 had severe dysphagia; no patients had severe dysphagia at 24 and 52 weeks post treatmentEP-104GI continues to be well

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities. VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2026. All dollar values are

F-X - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

F-10 - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026. Dr. Millard brings nearly 25 years of leadership experience in technical operatio

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. "We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company."   said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. "Their collective expertise across late-stage drug development, commer

Oppenheimer initiated coverage of Eupraxia Pharmaceuticals with a rating of Outperform and set a new price target of $17.00

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General Meeting of Shareholders (the "Meeting") held on June 18, 2026. Pursuant to a resolution passed by ballot vote, all of the seven nominees proposed by management for election to the Company’s board of directors (the "Board") at the Meeting and listed in the Company’s Management Information Circular da

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. Jefferies Global Healthcare Conference1x1 Meetings: June 3rd and 4th Presentation Date & Time: June 3rd, 2026, at 5:30PM – 6:00PM ETLocation: New York, NYWebcast registration link: https://event.summitcast.com/view/N

Stifel initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $25.00

SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2026. "Th